Kymera Therapeutics

131 articles about Kymera Therapeutics

• Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

  5/22/2023

  Kymera Therapeutics, Inc. today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.

• Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

  5/19/2023

  Kymera Therapeutics, Inc. has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253.

• Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

  5/18/2023

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented positive Phase 1 clinical data from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader.

• Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

  5/4/2023

  Kymera Therapeutics, Inc. today reported business highlights and financial results for the first quarter ended March 31, 2023.

• Kymera Therapeutics to Participate in Upcoming March Investor Conferences

  3/1/2023

  Kymera Therapeutics, Inc. today announced that the Company’s management team will attend the following upcoming investor events: Cowen 43rd Annual Health Care Conference in Boston, MA on March 6-8, 2023.

• Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

  2/23/2023

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.

• X-Chem and Kymera Expand Existing Partnership

  1/31/2023

  X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc.

• Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

  1/10/2023

  Kymera Therapeutics, Inc. today announced its research, development and corporate goals for 2023.

• Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

  1/4/2023

  Kymera Therapeutics, Inc. today announced the appointment of Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary.

• Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

  1/3/2023

  Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced the Company will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 9:00 AM PST.

• Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

  12/14/2022

  Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced positive clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 clinical trial, as well as updates on its three oncology programs: KT-413 (IRAKIMiD), KT-333 (STAT3) and KT-253 (MDM2).

• 

  First Protein Degrader Tested Outside Oncology Yields Promising Results

  12/14/2022

  Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa and atopic dermatitis.

• Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

  12/12/2022

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that preclinical data from collaborations for its STAT3 and IRAKIMiD degraders was presented at the American Society of Hematology (ASH) Annual Meeting.

• Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

  12/11/2022

  Kymera Therapeutics, Inc. presented preclinical data showing that KT-253, a novel MDM2 degrader, inhibited tumor growth as single agent and in combination with venetoclax in AML xenograft models.

• Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

  12/1/2022

  Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, shared webcast information for the virtual investor event that the Company will host on December 14, 2022, from 8:00-9:30 AM ET.

• Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

  11/3/2022

  Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced the appointment of Victor Sandor, M.D.C.M., to its Board of Directors.

• Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

  11/3/2022

  Kymera Therapeutics, Inc. reported business highlights and financial results for the third quarter ended September 30, 2022.

• Kymera Therapeutics to Report Third Quarter 2022 Results on November 3rd

  10/20/2022

  Kymera Therapeutics, Inc. will report third quarter 2022 financial results on November 3, 2022 and will host a conference call at 8:30 a.m. ET that day.

• Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

  10/13/2022

  Kymera Therapeutics, Inc. (NASDAQ: KYMR) will hold an investor webcast on December 14 to present clinical data from the KT-474 Phase 1 HS and AD patient cohort (Part C) and its oncology pipeline.

• 

  FDA Review: Abiomed, Mallinckrodt, Aro and More

  9/16/2022

  The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.